Heron Therapeutics (HRTX) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Heron Therapeutics (HRTX) over the last 5 years, with Q3 2025 value amounting to -$0.1.
- Heron Therapeutics' EPS (Weighted Average and Diluted) fell 23333.33% to -$0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.09, marking a year-over-year increase of 4375.0%. This contributed to the annual value of -$0.09 for FY2024, which is 8851.26% up from last year.
- Per Heron Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.1 for Q3 2025, which was down 23333.33% from -$0.02 recorded in Q2 2025.
- Over the past 5 years, Heron Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.03 during Q4 2024, and registered a low of -$0.63 during Q1 2022.
- In the last 5 years, Heron Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.15 in 2023 and averaged -$0.24.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 15474.62% in 2024, then crashed by 23333.33% in 2025.
- Heron Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.53 in 2021, then surged by 75.47% to -$0.13 in 2022, then skyrocketed by 61.54% to -$0.05 in 2023, then surged by 154.75% to $0.03 in 2024, then plummeted by 465.32% to -$0.1 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.1 in Q3 2025, compared to -$0.02 in Q2 2025 and $0.01 in Q1 2025.